Form 4: Eli Lilly Director Acquires Shares in Open Market Transaction

Director Jamere Jackson acquired 302.53 shares of Eli Lilly & Co. common stock at a price of $727.2 per share on November 18, 2024.

Summary

• On November 18, 2024, Jamere Jackson, a director at Eli Lilly & Co., purchased 302.53 shares of the company's common stock.
• The purchase was made at a price of $727.2 per share.
• Following this transaction, Mr. Jackson's total holdings of Eli Lilly common stock increased to 9,153.593 shares.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment, as it simply reports a transaction. The purchase by a director is a positive sign, but it's a routine disclosure.

Positives

• A director's purchase of company stock can be seen as a positive signal of confidence in the company's future prospects.

Industry Context

This transaction is a routine disclosure of insider trading activity, which is common for publicly traded companies like Eli Lilly. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Insider trading disclosures are a standard practice for all publicly listed companies in the US.
• The reporting of Form 4 filings is mandated by the SEC to ensure transparency and prevent insider trading abuses.
• Similar filings are made by directors and officers of other pharmaceutical companies such as Pfizer (PFE) and Johnson & Johnson (JNJ) when they engage in transactions involving their company's stock.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as it indicates a director's confidence in the company.

Key Dates

Keywords

Eli Lilly, LLY, Insider Trading, Stock Acquisition, Director, Jamere Jackson, SEC Form 4